Literature DB >> 33877384

Nutrient supplements from selected botanicals mediated immune modulation of the tumor microenvironment and antitumor mechanism.

Hui-Ming Chen1,2,3, Linus Sun4, Ping-Ying Pan1,2,3, Lu-Hai Wang5, Shu-Hsia Chen6,7,8,9.   

Abstract

Specific extracts of selected vegetables (SV) have been shown to benefit the survival of stage IIIb/IV non-small cell lung cancer patients in phase I/II studies and is currently in a phase III trial. However, the underlying mechanism of SV-mediated antitumor immune responses has not been elucidated. Our results indicate that SV modulated the NK and adoptive T cell immune responses in antitumor efficacy. Furthermore, antitumor effects of SV were also mediated by innate myeloid cell function, which requires both TLR and β-glucan signaling in a MyD88/TRIF and Dectin-1-dependent manner, respectively. Additionally, SV treatment reduced granulocytic myeloid-derived suppressor cell (MDSC) infiltration into the tumor and limited monocytic MDSC toward the M2-like functional phenotype. Importantly, SV treatment enhanced antigen-specific immune responses by augmenting the activation of antigen-specific TH1/TH17 cells in secondary lymphoid organs and proliferative response, as well as by reducing the Treg population in the tumor microenvironment, which was driven by SV-primed activated M-MDSC. Our results support the idea that SV can subvert immune-tolerance state in the tumor microenvironment and inhibit tumor growth. The present study suggests that features, such as easy accessibility, favorable clinical efficacy, no detectable side effects and satisfactory safety make SV a feasible, appealing and convincing adjuvant therapy for the treatment of cancer patients and prevent tumor recurrence and/or metastases.

Entities:  

Keywords:  Cancer immunotherapy; Immune modulating agents; MDSC; Nutrient supplement; TH1

Year:  2021        PMID: 33877384     DOI: 10.1007/s00262-021-02927-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  39 in total

1.  Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement.

Authors:  A S Sun; O Ostadal; V Ryznar; I Dulik; J Dusek; A Vaclavik; H C Yeh; C Hsu; H W Bruckner; T M Fasy
Journal:  Nutr Cancer       Date:  1999       Impact factor: 2.900

Review 2.  Nivolumab: a review in advanced squamous non-small cell lung cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

3.  Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.

Authors:  Laura C Cappelli; Anna Kristina Gutierrez; Alan N Baer; Jemima Albayda; Rebecca L Manno; Uzma Haque; Evan J Lipson; Karen B Bleich; Ami A Shah; Jarushka Naidoo; Julie R Brahmer; Dung Le; Clifton O Bingham
Journal:  Ann Rheum Dis       Date:  2016-06-15       Impact factor: 19.103

4.  Cancer undefeated.

Authors:  J C Bailar; H L Gornik
Journal:  N Engl J Med       Date:  1997-05-29       Impact factor: 91.245

Review 5.  Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.

Authors:  Elisa González-Rodríguez; Delvys Rodríguez-Abreu
Journal:  Oncologist       Date:  2016-06-15

6.  Chrysophanol Induces Apoptosis of Choriocarcinoma Through Regulation of ROS and the AKT and ERK1/2 Pathways.

Authors:  Whasun Lim; Changwon Yang; Fuller W Bazer; Gwonhwa Song
Journal:  J Cell Physiol       Date:  2016-06-02       Impact factor: 6.384

7.  Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients.

Authors:  A S Sun; H C Yeh; L H Wang; Y P Huang; H Maeda; A Pivazyan; C Hsu; E R Lewis; H W Bruckner; T M Fasy
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

8.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

9.  Epidemiology of lung cancer prognosis: quantity and quality of life.

Authors:  Ping Yang
Journal:  Methods Mol Biol       Date:  2009

Review 10.  Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.

Authors:  Erika Rijavec; Carlo Genova; Giulia Barletta; Giovanni Burrafato; Federica Biello; Maria Giovanna Dal Bello; Simona Coco; Anna Truini; Angela Alama; Francesco Boccardo; Francesco Grossi
Journal:  Expert Opin Biol Ther       Date:  2014-04-05       Impact factor: 4.388

View more
  1 in total

Review 1.  Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment.

Authors:  Tai-Na Wu; Hui-Ming Chen; Lie-Fen Shyur
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.